midazolam and allopurinol

midazolam has been researched along with allopurinol in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.88)18.2507
2000's9 (52.94)29.6817
2010's7 (41.18)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Beck, DJ; Bertino, JS; Gotschall, R; Kashuba, AD; Kearns, GL; Kulawy, RW; Leeder, JS; Nafziger, AN; Rocci, ML1
Bertino, JS; Bleakley, JF; Gaedigk, A; Gotschall, R; Kearns, GL; Kim, JS; Leeder, JS; Nafziger, AN; Streetman, DS1
Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y1
Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y1
Blake, M; Brown, KC; Gaedigk, A; Gotzkowsky, K; Hein, DW; Jones, AE; Kashuba, AD; van der Horst, C; Werner, RE1

Reviews

1 review(s) available for midazolam and allopurinol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for midazolam and allopurinol

ArticleYear
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Clinical pharmacology and therapeutics, 2003, Volume: 74, Issue:5

    Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase

2003
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
    Journal of clinical pharmacology, 2005, Volume: 45, Issue:12

    Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase

2005

Other Studies

14 other study(ies) available for midazolam and allopurinol

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index

2014
Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
    Clinical pharmacology and therapeutics, 1998, Volume: 64, Issue:3

    Topics: Acetyltransferases; Adult; Anti-Anxiety Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Female; Fluvoxamine; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Oxidoreductases, N-Demethylating; Phenotype; Reference Values; Selective Serotonin Reuptake Inhibitors; Time Factors; Xanthine Oxidase

1998
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:4

    Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Polymerase Chain Reaction; Xanthine Oxidase

2000
Variability in drug metabolizing enzyme activity in HIV-infected patients.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:5

    Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Female; HIV Infections; Humans; Interleukin-6; Male; Midazolam; Phenotype; Tumor Necrosis Factor-alpha; Xanthine Oxidase

2010